Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
189.66
+0.77 (0.41%)
Oct 8, 2025, 4:00 PM EDT - Market closed
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.74B in the quarter ending June 29, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to $90.63B, up 4.68% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$90.63B
Revenue Growth
+4.68%
P/S Ratio
5.02
Revenue / Employee
$656,242
Employees
138,100
Market Cap
456.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
JNJ News
- 13 hours ago - Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable - New York Post
- 23 hours ago - LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict - Business Wire
- 1 day ago - Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case - Reuters
- 1 day ago - TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis - PRNewsWire
- 1 day ago - Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill - PRNewsWire
- 1 day ago - Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses - PRNewsWire
- 2 days ago - Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Business Wire
- 2 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha